This video examines how a specific combination of KIR/KIR-ligand genotypes in high-risk neuroblastoma patients may be predictive of outcomes when adding dinutuximab to isotretinoin.
Amy K. Erbe, PhD
Advertisement
Articles by Amy K. Erbe, PhD
Advertisement
Latest Updated Articles
Marker May Predict Immunotherapy Benefit in High-Risk NeuroblastomaPublished: April 8th 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC
2
Tarlatamab May Offer New SOC for Relapsed ES-SCLC With Brain Metastases
3
Which Therapy Has the Best Efficacy in Transplant-Ineligible NDMM?
4
Companion Diagnostic Earns FDA Approval for Imlunestrant in Breast Cancer
5
